All we can do is look at the fundamentalsSome bad news for sure but let’s remember why this company is still attractive:
GTII last quarter (US millions):
revenue: 13.6
adjusted EBITDA: .5
Market cap: 2850
MedMen:
Revenue:19.2
EBITDA: didn’t realease but probably very negative
market cap: 2500
cannex:
revenue: 3.4 (or 10.3 if you include all NWCS earnings)
EBITDA: 1.78
market cap: 120
In other words the market values MedMen and green thumb as being worth 20X MORE than cannex even though they have comparable revenue. Now mmen and gtii should command a premium because they already have an established presence in a lot of states vs just one for cannex but I think we can all agree that the valuation for cannex is extraordinarily low compared to the industry considering they have the same growth prospects as every other US player